Vitamin D und postmenopausale Knochengesundheit

Bischoff-Ferrari, Heike A

Abstract: Fractures contribute significantly to morbidity and mortality of postmenopausal women. Among postmenopausal women aged 60 years and older, the mortality-adjusted residual lifetime risk of fracture has been estimated to be 44–65 %. Thus, effective strategies are urgently needed to prevent fractures among postmenopausal women. This review summarizes the available evidence that supports vitamin D3 supplementation at a dose of 800 IU per day as a strategy to reduce falls and fractures, including hip fractures, among postmenopausal women by about 20–30 %. This recommendation is supported by the Position Statement on Vitamin D of the International Osteoporosis Foundation, the 2011 World Osteoporosis Day Report, and the US Endocrine Society. Further, this recommendation is supported by the high prevalence of vitamin D deficiency among postmenopausal women. The prevalence of vitamin D deficiency (serum levels below 50 nmol/l or 20 ng/ml) among younger and older postmenopausal women has been found to be about 50 % in many countries around the world, with the highest prevalence (80 %) in older women with hip fractures. = Knochenfrakturen tragen in signifikantem Ausmaß zu Morbidität und Mortalität in der Postmenopause bei. Schätzungen des mortalitätsadjustierten Frakturrisikos in der verbleibenden Lebenszeit für Frauen im Alter ≥ 60 liegen zwischen 44 und 65%. Unbedingt notwendig sind also effektive Präventionsstrategien. Im Review-Beitrag wird die verfügbare Evidenz zur Vitamin-D3-Supplementierung (800 I.E. täglich) für eine 20- bis 30%ige Reduzierung von Sturzereignissen und (Hüft-)Frakturen bei postmenopausalen Frauen zusammengefasst. Diese Empfehlung wird gestützt von Positionspapieren der International Osteoporosis Foundation, des 2011 World Osteoporosis Day Report und der US-amerikanischen Endocrine Society, ferner von der hohen Prävalenz eines Vitamin-D-Mangels bei postmenopausalen Frauen. Die Vitamin-D-Mangel-Prävalenz (Serum-Konzentrationen <50 nmol/l bzw. 20 ng/ml) bei jüngeren wie älteren postmenopausalen Frauen wurde in vielen Ländern weltweit mit etwa 50 % angegeben, am höchsten (80 %) war sie bei älteren Frauen mit Hüftfrakturen.

DOI: <https://doi.org/10.1007/s00129-015-3727-7>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-207569>

Journal Article

Published Version

Originally published at:

Bischoff-Ferrari, Heike A (2015). Vitamin D und postmenopausale Knochengesundheit. *Der Gynäkologe*, 48(S1):1-6.

DOI: <https://doi.org/10.1007/s00129-015-3727-7>

Role of vitamin D in postmenopausal bone health

English Version

Epidemiology of fractures in postmenopausal women

After age 75, hip fractures are the most frequent type of fracture. Up to 50 % of postmenopausal women suffering a hip fracture will have permanent functional disability, 15–25 % will require long-term nursing home care, and up to 20 % will die within the first year after the event [1–10]. The exponential increase in hip fractures after age 75 translates into an estimated 1 in 3 women who will have sustained a hip fracture by their ninth decade of life [11].

Similar to hip fractures, the two other most common nonvertebral fractures – distal forearm and proximal humerus fractures – show a steep increase with age [12]. A further 1 in 3 women will have a prevalent vertebral fracture at age 80 [13]. Vertebral fractures also cause disability, back pain, [14], and decreased quality of life [15]. Postmenopausal women with a first vertebral fracture have a more than 19 % risk of developing a second vertebral fracture in the subsequent year [16]. Further, they have a 2.5-fold increased risk for any subsequent fracture [17], and a 2.8-fold increased mortality rate within the following 10 years [18]. Compared with hip fractures, the epidemiology of vertebral fractures is challenging with less than 30 % of vertebral fractures coming to clinical attention [19].

Vitamin D supplementation and fracture reduction in postmenopausal women

Vitamin D is essential for bone growth [20, 21] and preservation [22], and higher

25-hydroxyvitamin D [25(OH)D] levels are associated with higher bone density in younger and older adults [23]. Moreover, in double-blind randomized controlled trials (RCTs) among adults aged 65 and older, vitamin D supplementation increased bone density and reduced bone loss [24, 25].

Regarding the effect of vitamin D supplementation on fracture risk, the data from several study-level meta-analyses and two pooled individual participant-level (IPD) analyses are conflicting. While one trial-level meta-analysis of double-blind (RCTs) suggested an 18 % reduction of hip fractures and 20 % reduction of any nonvertebral fractures at a received dose of no less than 482 IU vitamin D per day [26], three study-level meta-analyses [27–29] and one pooled IPD analysis [30] of open-design and blinded trials suggested that vitamin D may have a neutral effect on total fractures [27] or may reduce hip fractures by 7–16 % independent of its dose if combined with calcium supplementation [27–29]. Finally, in the most recent 2012 pooled IPD analysis of 31,022 primarily postmenopausal women enrolled in double-blind RCTs on vitamin D, only an actual intake of 792–2,000 IU per day reduced the risk of fracture, with no benefit seen at a lower dose [31]. At the high intake range (median 800 IU per day), hip fracture risk was reduced by 30 % [31]. The discordant findings may in part be explained by different inclusion criteria of trials with respect to blinding and intake form (oral, injectable), or different accommodations for adherence. A dose–response relationship between vitamin D and fracture reduction as

documented in the 2009 meta-analyses of double-blind RCTs [26] and the 2012 IPD pooled analysis [31] is supported by epidemiologic data showing a significant positive trend between serum 25(OH)D concentrations and hip bone density [23] and lower extremity strength [32, 33].

Factors that may obscure the benefit of vitamin D are low adherence to treatment [34], low dose of vitamin D, or the use of less potent vitamin D₂ [35, 36]. Furthermore, open-design trials [37] may bias results toward a null effect because participants who know that they have been randomized to the control group may purchase vitamin D themselves as it is available without prescription.

The inclusion of mixed-quality studies may explain the recent findings and conclusion of the 2014 sequential meta-analysis by Bolland and colleagues [38, 39] that vitamin D may not be effective in fracture reduction. The authors included many studies that had little chance of demonstrating the true potential benefits of vitamin D. In particular, their analysis was based on a great mix of trials with blinded and open designs, follow-up periods that were often too short, administered doses that ranged widely, compliance that ranged widely, and endpoints that ranged from primary to secondary to un-prespecified, and consequently were adjudicated and nonadjudicated. The authors also chose to carry out their sequential meta-analysis with the goal of detecting a 15 % effect threshold for most outcomes and 5 % for mortality. We question this approach, as even

The German version of this article can be found at doi: [10.1007/s00129-015-3723-y](https://doi.org/10.1007/s00129-015-3723-y).

small effects carry an enormous benefit if an inexpensive intervention such as vitamin D is implemented broadly. In fact, for vitamin D plus calcium, the authors themselves document a significant 8 % reduction in total fractures and a significant 16 % reduction in hip fractures. Further, the authors document a significant 4 % reduction in overall mortality with vitamin D alone or in combination with calcium, which is particularly notable in the context of the limitations of the studies included. A fair question of a clinician may be, „Do I really stop supplementation with vitamin D when it has a significant reduction of hip fracture by 16 % (in conjunction with calcium) and of mortality by 4 % but not 5 %?“ Notably, on a public health level, a 4 % reduction of mortality generates an enormous population benefit.

Risk factors for vitamin D deficiency

Most vulnerable to vitamin D deficiency are older adults [40, 41], individuals living in northern latitudes with prolonged winters and thus low UVB exposure [42, 43], obese individuals [44], and individuals of all ages with a dark skin tone [23, 45, 46]. Other risk factors include medical conditions such as malabsorption and the use of anti-epileptic drugs [4].

Optimal 25(OH)D level for fracture prevention in postmenopausal women

A threshold for optimal serum 25(OH)D concentration and fracture prevention has been addressed in a recent benefit–risk analysis [47]. Based on data from RCTs and their achieved 25(OH)D levels in the treatment group, 75 nmol/l (30 ng/ml) is suggested as the best point estimate for an optimal threshold of 25(OH)D for fracture prevention. This threshold is further supported by epidemiologic data for hip bone density in younger and older adults [23], as well as a large bone-biopsy study in which mineralization defects were absent with serum levels of at least 75 nmol/l [48]. Also, the most recent pooled IPD analysis of double-blind RCTs found that among

Gynäkologe 2015 · [Suppl 1]: 48:S1–S5 DOI 10.1007/s00129-015-3727-7
© Springer-Verlag Berlin Heidelberg 2015

H. Bischoff-Ferrari

Role of vitamin D in postmenopausal bone health. English Version

Abstract

Fractures contribute significantly to morbidity and mortality of postmenopausal women. Among postmenopausal women aged 60 years and older, the mortality-adjusted residual lifetime risk of fracture has been estimated to be 44–65 %. Thus, effective strategies are urgently needed to prevent fractures among postmenopausal women. This review summarizes the available evidence that supports vitamin D3 supplementation at a dose of 800 IU per day as a strategy to reduce falls and fractures, including hip fractures, among postmenopausal women by about 20–30 %. This recommendation is supported by the Position Statement on Vitamin D of the International Osteoporosis

Foundation, the 2011 World Osteoporosis Day Report, and the US Endocrine Society. Further, this recommendation is supported by the high prevalence of vitamin D deficiency among postmenopausal women. The prevalence of vitamin D deficiency (serum levels below 50 nmol/l or 20 ng/ml) among younger and older postmenopausal women has been found to be about 50 % in many countries around the world, with the highest prevalence (80 %) in older women with hip fractures.

Keywords

Menopause · Osteoporosis · Fractures · Fall events · Calcium

Vitamin D und postmenopausale Knochengesundheit. Englische Version

Zusammenfassung

Knochenfrakturen tragen in signifikantem Ausmaß zu Morbidität und Mortalität in der Postmenopause bei. Schätzungen des mortalitätsadjustierten Frakturrisikos in der verbleibenden Lebenszeit für Frauen im Alter ≥ 60 liegen zwischen 44 und 65 %. Unbedingt notwendig sind also effektive Präventionsstrategien. Im Review-Beitrag wird die verfügbare Evidenz zur Vitamin-D3-Supplementierung (800 I.E. täglich) für eine 20- bis 30%ige Reduzierung von Sturzereignissen und (Hüft-)Frakturen bei postmenopausalen Frauen zusammengefasst. Diese Empfehlung wird gestützt von Positionspapieren der International Osteoporosis Foundation, des

2011 World Osteoporosis Day Report und der US-amerikanischen Endocrine Society, ferner von der hohen Prävalenz eines Vitamin-D-Mangels bei postmenopausalen Frauen. Die Vitamin-D-Mangel-Prävalenz (Serum-Konzentrationen < 50 nmol/l bzw. 20 ng/ml) bei jüngeren wie älteren postmenopausalen Frauen wurde in vielen Ländern weltweit mit etwa 50 % angegeben, am höchsten (80 %) war sie bei älteren Frauen mit Hüftfrakturen.

Schlüsselwörter

Menopause · Osteoporose · Frakturen · Sturzereignisse · Kalzium

over 4,000 primarily postmenopausal women, fracture risk declined significantly with higher baseline 25(OH)D levels [31]. Comparing individuals with starting levels of less than 30 nmol/l with those on starting levels of 61 nmol/l and above, the latter group had a 37 % lower risk of hip fracture and a 31 % lower risk of any nonvertebral fracture [31].

The 25(OH)D threshold of at least 75 nmol/l (30 ng/ml) for optimal fracture prevention is supported by the 2010 IOF position statement on vitamin D [2] and the 2011 US Endocrine Society Task Force on Vitamin D [4]. By

contrast, the 2010 Institute of Medicine recommendations suggest that 50 nmol/l may be sufficient for bone health in the population, although (1) no single trial that reached 50 nmol/l in their treatment group achieved fracture reduction, and (2) in their fracture assessment section the IOM report reads that only studies that achieved 25(OH)D levels of at least 75 nmol/l showed significant fracture reduction [49]. Current intake recommendations of 800 IU vitamin D per day will shift over 97 % of postmenopausal women to at least 50 nmol/l and about 50 % to 75 nmol/l [49, 50].

Infobox 1 Key messages

1. Vitamin D supplementation reduces the risk of fracture; however, this benefit is dose dependent. All recent recommendations support 800 IU vitamin D per day for fracture reduction.
2. Vitamin D reduces fracture risk through both its benefit on bone and its effect on fall reduction.
3. To achieve optimal fracture reduction, a 25(OH)D threshold of at least 61 nmol/l and ideally 75 nmol/l may be warranted.

Vitamin D benefits in fracture prevention and the effect of vitamin D on muscle

The beneficial effect of vitamin D on calcium absorption and bone mineral density may not be the only explanation for its protective effect against fractures [26]. In fact, vitamin D deficiency may cause muscular impairment even before adverse effects on bone occur [51].

Four lines of evidence support the role of vitamin D in muscle health. *First*, proximal muscle weakness is a prominent feature of the clinical syndrome of vitamin D deficiency [52]. Clinical findings in vitamin D deficiency myopathy include proximal muscle weakness, diffuse muscle pain, and gait impairments such as a waddling way of walking [53]. *Second*, the vitamin D receptor (VDR) is expressed in human muscle tissue [54–56], and VDR activation may promote de novo protein synthesis in muscle [56–58]. Mice lacking the VDR show a skeletal muscle phenotype with smaller and variable muscle fibers and persistence of immature muscle gene expression during adult life [59, 60]. *Third*, several observational studies suggest a positive association between 25(OH)D and muscle strength or lower extremity function in older persons [32, 33]. *Fourth*, vitamin D supplementation increases muscle strength and balance [61, 62], and reduces the risk of falling in community-dwelling individuals [62–64], as well as in institutionalized individuals [61, 65], in several double-blind RCTs summarized in a 2009 meta-analysis [66].

Thus, relevant to fracture prevention in older postmenopausal women,

vitamin D supplementation for fall prevention should not be delayed. This suggestion is in line with the Agency for Healthcare Research and Quality (AHRQ) of the US Preventive Services Task Force [67], the 2010 American Geriatric Society/British Geriatric Society Clinical Practice Guideline [68], the 2010 assessment by the IOF [2], and the 2011 Endocrine Society Recommendations, all four of which identified vitamin D as an effective intervention to prevent falling in older adults.

Amount of vitamin D needed to overcome vitamin D deficiency

Most healthy adults overcome vitamin D deficiency by reaching 25(OH)D serum concentrations of about 50 nmol/l with 600–800 IU vitamin D per day [50, 69]. Among healthy postmenopausal white women, a recent multidose comparison suggested that a dose of 1,600 IU per day may be sufficient for 97.5 % of the study population to reach 75 nmol/l [69]. Notably, however, this dose has not been tested for fracture prevention.

Conclusion

Postmenopausal women have a high risk of vitamin D deficiency and vitamin D is relevant to bone and muscle health, as supported by several lines of evidence summarized in this review article. Meta-analyses of double-blind RCTs provide strong support for vitamin D supplementation at a dose of 800 IU per day in postmenopausal women for fall and fracture prevention.

Corresponding address

Prof. Dr. med. H. Bischoff-Ferrari

Klinik für Geriatrie, Universitätsspital Zürich, Lehrstuhl Geriatrie und Altersforschung Rämistrasse 100, 8091 Zürich, Schweiz
Heike.Bischoff@usz.ch

Compliance with ethical guidelines

Conflict of interest. Heike Bischoff-Ferrari declares that she has no conflict of interest.

This article does not contain any studies with human participants or animals performed by any of the authors.

References

1. Nguyen ND, Ahlborg HG, Center JR et al (2007) Residual lifetime risk of fractures in women and men. *J Bone Miner Res* 12:12
2. Dawson-Hughes B, Mithal A, Bonjour JP et al (2010) IOF position statement: vitamin D recommendations for older adults. *Osteoporos Int* 21(7):1151–1154
3. Bischoff Ferrari HA (2011) Three steps to unbreakable bones: the 2011 World Osteoporosis Day Report. http://www.iofbonehealth.org/WOD_11/WOD11-Report.pdf. Accessed 3 June 2012
4. Holick MF, Binkley NC, Bischoff-Ferrari HA et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 96(7):1911–1930
5. van Schoor NM, Lips P (2011) Worldwide vitamin D status. *Best Pract Res Clin Endocrinol Metab* 25(4):671–680
6. Bischoff-Ferrari HA, Can U, Staehelin HB et al (2008) Severe vitamin D deficiency in Swiss hip fracture patients. *Bone* 42(3):597–602
7. LeBoff MS, Kohlmeier L, Hurwitz S et al (1999) Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. *JAMA* 281(16):1505–1511
8. Magaziner J, Hawkes W, Hebel JR et al (2000) Recovery from hip fracture in eight areas of function. *J Gerontol A Biol Sci Med Sci* 55(9):M498–M507
9. Tinetti ME, Williams CS (1997) Falls, injuries due to falls, and the risk of admission to a nursing home. *N Engl J Med* 337(18):1279–1284
10. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ (1985) Epidemiology of osteoporosis and osteoporotic fractures. *Epidemiol Rev* 7:178–208
11. Birge SJ, Morrow-Howell N, Proctor EK (1994) Hip fracture. *Clin Geriatr Med* 10(4):589–609
12. Barrett JA, Baron JA, Karagas MR, Beach ML (1999) Fracture risk in the U.S. Medicare population. *J Clin Epidemiol* 52(3):243–249
13. Nevitt MC, Cummings SR, Stone KL et al (2005) Risk factors for a first incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures. *J Bone Miner Res* 20(1):131–140
14. Nevitt MC, Ettinger B, Black DM et al (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. *Ann Intern Med* 128(10):793–800
15. Silverman SL, Minshall ME, Shen W et al (2001) The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. *Arthritis Rheum* 44(11):2611–2619
16. Lindsay R, Silverman SL, Cooper C et al (2001) Risk of new vertebral fracture in the year following a fracture. *JAMA* 285(3):320–323
17. Center JR, Biuc D, Nguyen TV, Eisman JA (2007) Risk of subsequent fracture after low-trauma fracture in men and women. *JAMA* 297(4):387–394
18. Hassserius R, Karlsson MK, Jonsson B et al (2005) Long-Term Morbidity and Mortality After a Clinically Diagnosed Vertebral Fracture in the

- Elderly — a 12- and 22-year Follow-Up of 257 Patients. *Calcif Tissue Int* 76(4):235–242
19. Cooper C, Melton LJ III (1992) Epidemiology of osteoporosis. *Trends Endocrinol Metab* 3(4):224–229
 20. Specker BL, Ho ML, Oestreich A et al (1992) Prospective study of vitamin D supplementation and rickets in China. *J Pediatr* 120(5):733–739
 21. Aksnes L, Aarskog D (1982) Plasma concentrations of vitamin D metabolites in puberty: effect of sexual maturation and implications for growth. *J Clin Endocrinol Metab* 55(1):94–101
 22. Smith R, Dent CE (1969) Vitamin D requirements in adults. Clinical and metabolic studies on seven patients with nutritional osteomalacia. *Bibl Nutr Dieta* 13:44–45
 23. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B (2004) Positive association between 25-hydroxyvitamin D levels and bone mineral density: a population-based study of younger and older adults. *Am J Med* 116(9):634–639
 24. Dawson-Hughes B, Dallal GE, Krall EA et al (1991) Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women. *Ann Intern Med* 115(7):505–512
 25. Ooms ME, Roos JC, Bezemer et al (1995) Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. *J Clin Endocrinol Metab* 80(4):1052–1058
 26. Bischoff-Ferrari HA, Willett WC, Wong JB et al (2009) Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. *Arch Intern Med* 169(6):551–561
 27. Cranney A, Horsley T, O'Donnell S et al (2007) Effectiveness and safety of vitamin D in relation to bone health. *Evid Rep Technol Assess (Full Rep)* 158:1–235
 28. Boonen S, Lips P, Bouillon R et al (2007) Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. *J Clin Endocrinol Metab* 92(4):1415–1423
 29. Avenell A, Gillespie WJ, Gillespie LD, O'Connell D (2009) Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. *Cochrane Database Syst Rev* 2:CD000227
 30. DIPART (2010) Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. *BMJ* 340:b5463
 31. Bischoff-Ferrari HA, Orav EJ, Willett WC et al (2012) A pooled analysis of vitamin D dose requirements for fracture prevention. *N Engl J Med* 367(1):40–49
 32. Bischoff-Ferrari HA, Dietrich T, Orav EJ et al (2004) 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged ≥ 60 y. *Am J Clin Nutr* 80(3):752–758
 33. Wicherts IS, van Schoor NM, Boeke AJ et al (2007) Vitamin D status predicts physical performance and its decline in older persons. *J Clin Endocrinol Metab* 6:6
 34. Grant AM, Avenell A, Campbell MK et al (2005) Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. *Lancet* 365(9471):1621–1628
 35. Armas LA, Hollis BW, Heaney RP (2004) Vitamin D2 is much less effective than vitamin D3 in humans. *J Clin Endocrinol Metab* 89(11):5387–5391
 36. Houghton LA, Vieth R (2006) The case against ergocalciferol (vitamin D2) as a vitamin supplement. *Am J Clin Nutr* 84(4):694–697
 37. Porthouse J, Cockayne S, King C et al (2005) Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. *BMJ* 330(7498):1003
 38. Bolland MJ, Grey A, Gamble GD, Reid IR (2014) The effect of vitamin D on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. *Lancet* (online)
 39. Bischoff-Ferrari HA, Orav EJ, Willett WC, Dawson-Hughes B (2014) The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes. *Lancet Diabetes Endocrinol* 2(5):363–364
 40. McKenna MJ (1992) Differences in vitamin D status between countries in young adults and the elderly. *Am J Med* 93(1):69–77
 41. Theiler R, Stahelin HB, Tyndall A et al (1999) Calcidiol, calcitriol and parathyroid hormone serum concentrations in institutionalized and ambulatory elderly in Switzerland. *Int J Vitam Nutr Res* 69(2):96–105
 42. Webb AR, Kline L, Holick MF (1988) Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. *J Clin Endocrinol Metab* 67(2):373–378
 43. Dawson-Hughes B, Harris SS, Dallal GE (1997) Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. *Am J Clin Nutr* 65(1):67–71
 44. Parikh SJ, Edelman M, Uwaiso GI et al (2004) The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. *J Clin Endocrinol Metab* 9(3):1196–1199
 45. Looker AC, Dawson-Hughes B, Calvo MS et al (2002) Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. *Bone* 30(5):771–777
 46. Nesby-O'Dell S, Scanlon KS, Cogswell ME et al (2002) Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988–1994. *Am J Clin Nutr* 76(1):187–192
 47. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, Hathcock J, Giovannucci E, Willett WC (2010) Benefit-Risk Assessment of Vitamin D Supplementation. *Osteoporos Int* 21(7):1121–1132
 48. Priemel M, von Demarus C, Klatte TO et al (2011) Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. *J Bone Miner Res* 25(2):305–312
 49. IOM (2010) Dietary Reference Ranges for Calcium and Vitamin D. <http://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D.aspx>. Accessed 13 Feb 2012
 50. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B et al (2010) Benefit-risk assessment of vitamin D supplementation. *Osteoporos Int* 21(7):1121–1132
 51. Glerup H, Mikkelsen K, Poulsen L et al (2000) Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. *Calcif Tissue Int* 66(6):419–424
 52. Al-Shoha A, Qiu S, Palnitkar S, Rao DS (2009) Osteomalacia with bone marrow fibrosis due to severe vitamin D deficiency after a gastrointestinal bypass operation for severe obesity. *Endocr Pract* 15(6):528–533
 53. Schott GD, Wills MR (1976) Muscle weakness in osteomalacia. *Lancet* 1(7960):626–629
 54. Bischoff-Ferrari HA, Borchers M, Gudat F et al (2004) Vitamin D receptor expression in human muscle tissue decreases with age. *J Bone Miner Res* 19(2):265–269
 55. Ceglia L, da Silva Morais M, Park LK et al (2010) Multi-step immunofluorescent analysis of vitamin D receptor loci and myosin heavy chain isoforms in human skeletal muscle. *J Mol Histol* 41(2–3):137–142
 56. Ceglia L, Niramitmahapanya S, da Silva Morais M et al (2013) A randomized study on the effect of vitamin D3 supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women. *J Clin Endocrinol Metab* 98(12):E1927–E1935
 57. Sorensen OH, Lund B, Saltin B et al (1979) Myopathy in bone loss of ageing: improvement by treatment with 1 alpha-hydroxycholecalciferol and calcium. *Clin Sci (Colch)* 56(2):157–161
 58. Freedman LP (1999) Transcriptional targets of the vitamin D3 receptor-mediating cell cycle arrest and differentiation. *J Nutr* 129(2S Suppl):581S–586S
 59. Bouillon R, Bischoff-Ferrari H, Willett W (2008) Vitamin D and health: perspectives from mice and man. *J Bone Miner Res* 28:28
 60. Endo I, Inoue D, Mitsui T et al (2003) Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. *Endocrinology* 144(12):5138–5144
 61. Bischoff HA, Stahelin HB, Dick W et al (2003) Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. *J Bone Miner Res* 18(2):343–351
 62. Pfeifer M, Begerow B, Minne HW et al (2008) Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. *Osteoporos Int* 16:16
 63. Bischoff-Ferrari HA, Orav EJ, Dawson-Hughes B (2006) Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. *Arch Intern Med* 166(4):424–430
 64. Pfeifer M, Begerow B, Minne HW et al (2000) Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. *J Bone Miner Res* 15(6):1113–1118
 65. Broe KE, Chen TC, Weinberg J et al (2007) A higher dose of vitamin D reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. *J Am Geriatr Soc* 55(2):234–239
 66. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB et al (2009) Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. *BMJ* 339(1):339b3692
 67. Michael YL, Whitlock EP, Lin JS et al (2011) Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the u.s. Preventive services task force. *Ann Intern Med* 153(12):815–825

-
68. AGS/BGS (2011) AGS/BGS Guidelines on Fall Prevention in older Persons. http://www.patientsafetysolutions.com/docs/February_2011_Updated_Fall_Prevention_Guide-lines.htm. Accessed 13 Feb 2012
69. Gallagher JC, Sai A, Templin TL, Smith L (2012) Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. *Ann Intern Med* 156(6):425–437